Avery Dennison has launched two proprietary adhesives for pharmaceutical labeling to partner its paper and film facestocks. Fasson S2000NP and Fasson S692NP are said to provide pharmaceutical manufacturers with high mandrel performance, low migration, long-term adhesion and regulatory compliance.
Fasson S2000NP’s high mandrel performance makes it suitable for the tight-diameter curves of glass, PE, and PP ampoules, vials and test tubes, and is also suitable for sterilization by autoclaving, ETO and gamma radiation. Fasson S2000NP partners Fasson LW supercalendered, double-machine-coated lightweight paper.
Jan΄t Hart, global business director, pharmaceutical segment, for Avery Dennison Roll Materials, said: “We have developed these two new adhesives to meet today’s high standards in pharmaceutical packaging, and with long-term sustainability of the formulations in mind. Together, they can meet a broad range of applications in the pharmaceuticals industry for ethical and OTC medicines and a variety of container substrates.”
Fasson S692NP is a clear, permanent acrylic-based adhesive claimed to offer a particularly low migration risk, excellent UV resistance and good adhesion to apolar substrates. It complies with European food directives, FDA 175.105, and the German BfR recommendations XIV for direct contact with dry and moist, non-fatty foodstuffs. Fasson S692NP can partner Fasson LW paper facestock, or a choice of Fasson film facestocks – Fasson PE85 Top and Fasson PP Top White and Clear.
“These two new adhesives”, continued ΄t Hart, “are formulated with the specific needs of today’s global pharmaceutical manufacturers in mind, and our global pharmaceutical team has taken those needs seriously. Since the 1980s, we have been working with leading pharmaceutical manufacturers to enable them to benefit from the cleanliness, versatility, and ease of self-adhesive labels, within the context of their highlyregulated environment. We provide change notification for both component and process changes in our pharmaceuticals product portfolio; and our change management process involves holding ‘safety’ stocks of approved materials in case pharmaceutical manufacturers require to requalify labelstock where anything has been changed.”